GleamWall
中文EN

BMY BRISTOL MYERS SQUIBB CO

Pharmaceutical Preparations · NYSE · SEC CIK 14272 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.2%
TTM net income YoY53.1%
TTM EPS YoY51.9%
Revenue 3-yr CAGR3.6%
Net income 3-yr CAGR3.7%

Margins

Gross margin69.2%
Operating margin—
Net margin18.5%
FCF margin18.6%
EBITDA margin—

Returns

ROE44.1%
ROA10.0%
ROIC (approx.)—
Asset turnover0.54x

Leverage & solvency

Liabilities / assets73.6%
Debt / equity1.83x
Current ratio1.59x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.15x
Accruals ratio-1.5%
Payout ratio55.4%
Capex / revenue2.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$13.07B$12.97B$11.49B$12.50B$12.22B$12.27B$11.20B$12.34B
Cost of revenue$4.15B$3.73B$3.42B$4.10B$3.44B$3.37B$3.03B$4.81B
Gross profit$8.92B$9.25B$8.07B$8.40B$8.79B$8.90B$8.17B$7.53B
R&D expense$2.37B$2.96B$2.65B$2.59B$2.53B$2.58B$2.26B$3.19B
SG&A expense$1.70B$1.83B$1.62B$2.18B$1.79B$1.71B$1.58B$2.14B
Interest expense$403.00M$407.00M$411.00M$432.00M$480.00M$485.00M$494.00M$496.00M
Pretax income$2.54B$4.09B$3.24B$1.47B$3.11B$1.77B$2.97B$175.00M
Income tax$374.00M$770.00M$561.00M$384.00M$919.00M$460.00M$509.00M$99.00M
Net income$2.16B$3.32B$2.68B$1.09B$2.20B$1.31B$2.46B$72.00M
EPS (basic)1.061.621.31—1.080.641.21—
EPS (diluted)1.051.621.31—1.080.641.20—
Dividends declared per share0.630.630.630.630.620.620.620.62
Weighted avg. shares (diluted)2.05B2.05B2.05B—2.04B2.04B2.04B—
Balance sheet
Cash & equivalents$9.57B$8.72B$9.57B$10.21B$15.73B$12.61B$10.88B$10.35B
Short-term investments$3.01B$2.35B$912.00M$464.00M$776.00M$1.00B$907.00M$513.00M
Receivables$9.19B$9.08B$7.95B$9.59B$9.62B$9.71B$9.06B$9.01B
Inventory$2.70B$2.74B$2.76B$2.69B$2.76B$2.74B$2.67B$2.56B
Current assets$29.77B$28.58B$27.21B$29.39B$35.63B$33.22B$30.78B$29.78B
PP&E, net$7.97B$7.79B$7.66B$7.54B$7.35B$7.37B$7.21B$7.14B
Goodwill$21.73B$21.74B$21.74B$21.75B$21.75B$21.78B$21.74B$21.72B
Intangibles$16.94B$17.39B$18.24B$19.10B$20.46B$21.38B$22.49B$23.31B
Total assets$88.77B$87.63B$86.48B$90.04B$96.89B$94.68B$92.43B$92.60B
Current liabilities$18.75B$18.66B$19.16B$23.42B$28.14B$27.53B$24.07B$23.77B
Short-term debt$1.03B$1.03B$2.31B$2.26B$4.51B$4.71B$3.55B$2.05B
Long-term debt$41.85B$42.09B$42.15B$42.85B$44.47B$44.47B$46.16B$47.60B
Total debt$42.88B$43.12B$44.46B$45.11B$48.98B$49.19B$49.71B$49.65B
Total liabilities$65.37B$65.31B$66.37B$71.53B$78.29B$77.19B$74.98B$76.22B
Shareholders' equity$23.40B$22.32B$20.07B$18.47B$18.55B$17.43B$17.39B$16.34B
Net debt$33.30B$34.40B$34.89B$34.90B$33.25B$36.57B$38.84B$39.30B
Cash flow statement
Operating cash flow$4.18B$3.39B$1.10B$1.97B$6.31B$3.92B$1.95B$4.44B
Capital expenditure$344.00M$305.00M$347.00M$370.00M$320.00M$361.00M$260.00M$378.00M
Free cash flow$3.84B$3.09B$757.00M$1.60B$5.99B$3.56B$1.69B$4.06B
Investing cash flow-$2.10B-$1.61B-$131.00M-$1.46B-$1.70B-$473.00M-$499.00M-$196.00M
Financing cash flow-$1.22B-$2.63B-$1.56B-$6.03B-$1.49B-$1.84B-$993.00M-$1.64B
Depreciation & amortization$151.00M$139.00M$594.00M$977.00M$159.00M$165.00M$1.01B$1.88B
Stock-based compensation$138.00M$135.00M$146.00M$133.00M$139.00M$138.00M$144.00M$120.00M
Dividends paid$1.29B$1.29B$1.28B$1.26B$1.26B$1.26B$1.26B$1.22B
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 74 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.